Stonepine Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100,000	Closed	-$1.58M	–	91
2025 Q4	$1.58M	Sell	100,000 -205,000	-67%	-$2.6M	1.25%	27
2025 Q3	$3.65M	Sell	305,000 -299,066	-50%	-$2.39M	2.97%	9
2025 Q2	$4.57M	Buy	604,066 +13,324	+2%	+$80.1K	4.5%	7
2025 Q1	$3.26M	Buy	590,742 +258,842	+78%	+$1.6M	3.17%	9
2024 Q4	$1.91M	Buy	+331,900	New	+$3.18M	1.54%	20
2022 Q2	–	Sell	-119,972	Closed	-$8.54M	–	27
2022 Q1	$8.54M	Buy	+119,972	New	+$7.81M	3.54%	11
2019 Q4	–	Sell	-129,867	Closed	-$7.8M	–	26
2019 Q3	$7.8M	Buy	129,867 +64,383	+98%	+$4.78M	7.57%	4
2019 Q2	$5.53M	Buy	65,484 +4,644	+8%	+$418K	3.8%	10
2019 Q1	$5.81M	Buy	+60,840	New	+$5.46M	3.34%	12
2018 Q1	–	Sell	-218,434	Closed	-$12.8M	–	33
2017 Q4	$12.8M	Sell	218,434 -171,566	-44%	-$8.59M	7.68%	5
2017 Q3	$18.3M	Sell	390,000 -102,265	-21%	-$4.11M	10.76%	2
2017 Q2	$17.7M	Buy	492,265 +307,166	+166%	+$9.82M	9.56%	2
2017 Q1	$5.7M	Sell	185,099 -46,814	-20%	-$1.46M	3.21%	11
2016 Q4	$7.77M	Buy	+231,913	New	+$6.65M	4.63%	9
2016 Q1	–	Sell	-71,147	Closed	-$2.35M	–	20
2015 Q4	$2.35M	Buy	+71,147	New	+$2.32M	2.75%	10